Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04628949 · ClinicalTrials.gov registry record · NA
A Single-Use Duodenoscope in a Real-World Setting
A NA study of Endoscopic Retrograde Cholangiopancreatography (ERCP), sponsored by Ambu A/S.
- Completed
- Registry status
- NA
- Development phase
- 248
- Enrollment target
- 9
- Study locations
NCT04628949 is a NA study of Endoscopic Retrograde Cholangiopancreatography (ERCP) that has completed, run by Ambu A/S. The registered enrollment target is 248 participants. The trial reports 9 study locations across 8 states.
The verdict
NCT04628949, a NA study of Endoscopic Retrograde Cholangiopancreatography (ERCP), has completed, sponsored by Ambu A/S.
- COMPLETED
- Registry status
- NA
- Development phase
- 248 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study will assess how the aScope™ Duodeno endoscope performs in procedures that treat problems of the bile and pancreatic ducts.
Conditions Studied
Interventions
- DEVICE aScope™ Duodeno endoscope and aBox™ Duodeno
Study Locations (9)
New York
- NYU Langone Health - New York
- Mount Sinai South Nassau - Oceanside
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- University of Colorado Hospital - Aurora
Illinois
- Southwest Gastroenterology - Oak Lawn
Indiana
- Indiana University, University Hospital - Indianapolis
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cleveland Clinic Foundation - Cleveland
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2021-01-25 |
| Est. Completion | 2022-02-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04628949
The ClinicalTrials.gov registry entry for NCT04628949 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ambu A/S, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endoscopic Retrograde Cholangiopancreatography (ERCP) appearing as the primary indexed condition, and to 1 intervention - of which aScope™ Duodeno endoscope and aBox™ Duodeno is the first listed.
NCT04628949 reports 9 study locations spanning 8 distinct geographic areas - top geographies include New York, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT04628949 about?
NCT04628949 is a clinical study titled "A Single-Use Duodenoscope in a Real-World Setting". This study will assess how the aScope™ Duodeno endoscope performs in procedures that treat problems of the bile and pancreatic ducts.
What is the current status of trial NCT04628949?
This trial is currently completed. It is a NA study. The enrollment target is 248 participants. The study started on 2021-01-25. Estimated completion is 2022-02-28.
What conditions does trial NCT04628949 study?
This clinical trial studies the following conditions: Endoscopic Retrograde Cholangiopancreatography (ERCP).
What interventions are being tested in trial NCT04628949?
The interventions under investigation include: aScope™ Duodeno endoscope and aBox™ Duodeno (DEVICE).
Who is sponsoring clinical trial NCT04628949?
This trial is sponsored by Ambu A/S, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04628949 being conducted?
This trial has 9 study locations across Alabama, Colorado, Illinois, Indiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endoscopic Retrograde Cholangiopancreatography (ERCP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.